These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 23401350)

  • 1. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?
    Liu X; Mayes MD; Pedroza C; Draeger HT; Gonzalez EB; Harper BE; Reveille JD; Assassi S
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1375-80. PubMed ID: 23401350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.
    Wu M; Baron M; Pedroza C; Salazar GA; Ying J; Charles J; Agarwal SK; Hudson M; Pope J; Zhou X; Reveille JD; Fritzler MJ; Mayes MD; Assassi S
    Arthritis Rheumatol; 2017 Sep; 69(9):1871-1878. PubMed ID: 28575534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
    Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
    Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
    Elhaj M; Charles J; Pedroza C; Liu X; Zhou X; Estrada-Y-Martin RM; Gonzalez EB; Lewis DE; Draeger HT; Kim S; Arnett FC; Mayes MD; Assassi S
    J Rheumatol; 2013 Jul; 40(7):1114-20. PubMed ID: 23588945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.
    Assassi S; Sharif R; Lasky RE; McNearney TA; Estrada-Y-Martin RM; Draeger H; Nair DK; Fritzler MJ; Reveille JD; Arnett FC; Mayes MD;
    Arthritis Res Ther; 2010; 12(5):R166. PubMed ID: 20813056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
    De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
    J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
    Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
    Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
    Ghuman A; Khanna D; Lin CJF; Furst DE; Raghu G; Martinez FJ; Zucchetto M; Huang S; Jennings A; Nihtyanova SI; Denton CP
    Rheumatology (Oxford); 2024 Feb; 63(2):472-481. PubMed ID: 37228011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
    Štorkánová H; Oreská S; Špiritović M; Heřmánková B; Bubová K; Komarc M; Pavelka K; Vencovský J; Distler JHW; Šenolt L; Bečvář R; Tomčík M
    Sci Rep; 2021 Jan; 11(1):1. PubMed ID: 33414495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRF5 polymorphism predicts prognosis in patients with systemic sclerosis.
    Sharif R; Mayes MD; Tan FK; Gorlova OY; Hummers LK; Shah AA; Furst DE; Khanna D; Martin J; Bossini-Castillo L; Gonzalez EB; Ying J; Draeger HT; Agarwal SK; Reveille JD; Arnett FC; Wigley FM; Assassi S
    Ann Rheum Dis; 2012 Jul; 71(7):1197-202. PubMed ID: 22440820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease.
    Assassi S; Li N; Volkmann ER; Mayes MD; Rünger D; Ying J; Roth MD; Hinchcliff M; Khanna D; Frech T; Clements PJ; Furst DE; Goldin J; Bernstein EJ; Castelino FV; Domsic RT; Gordon JK; Hant FN; Shah AA; Shanmugam VK; Steen VD; Elashoff RM; Tashkin DP
    Arthritis Rheumatol; 2021 Jun; 73(6):1005-1013. PubMed ID: 33350170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
    Bernstein EJ; Denton CP; Huang S; Khanna D
    Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
    Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
    Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.